{"id":154760,"date":"2024-03-31T20:00:00","date_gmt":"2024-04-01T00:00:00","guid":{"rendered":"https:\/\/platohealth.ai\/?p=154760"},"modified":"2024-03-31T20:00:00","modified_gmt":"2024-04-01T00:00:00","slug":"goalie-intramuscular-vs-enteral-penicillin-prophylaxis-to-prevent-progression-of-latent-rhd-trial","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/goalie-intramuscular-vs-enteral-penicillin-prophylaxis-to-prevent-progression-of-latent-rhd-trial\/","title":{"rendered":"GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"\n
\n

Studies<\/h3>\n\n\n\n\n\n\n\n\n\n <\/tr>\n<\/table><\/div>\n
\n

Detailed Descriptions<\/h3>\n

Study First Submitted Date<\/td>\n2023-01-04<\/td>\n<\/tr>\n
Study First Posted Date <\/td>\n2023-01-23<\/td>\n<\/tr>\n
Last Update Posted Date<\/td>\n2023-05-08<\/td>\n<\/tr>\n
Start Month Year<\/td>\nApril 1, 2024<\/td>\n<\/tr>\n
Primary Completion Month Year<\/td>\nMarch 31, 2027<\/td>\n<\/tr>\n
Verification Month Year<\/td>\nMay 2023<\/td>\n<\/tr>\n
Verification Date<\/td>\n2023-05-31<\/td>\n<\/tr>\n
Last Update Posted Date<\/td>\n2023-05-08<\/td>\n<\/tr>\n
\n\n\n
Sequence:<\/td>\n20718240<\/td>\n<\/tr>\n
Description<\/td>\nGOALIS is a randomized controlled trial developed to provide high quality contemporary evidence on the efficacy of oral penicillin as RHD prophylaxis. Aim 1: To compare the proportion of children aged 5-17 years with latent RHD receiving oral penicillin prophylaxis who progress to worse valvular disease at 2-years compared to children who receive IM penicillin prophylaxis. Aim 2: To evaluate the economic equivalence and cost-effectiveness of oral penicillin compared to IM penicillin, after echocardiographic screening for latent RHD detection. Aim 3: Compare patient-reported outcomes (treatment acceptance, treatment satisfaction, and health-related quality of life) between children receiving oral and IM penicillin prophylaxis.<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Facilities<\/h3>\n\n\n <\/tr>\n\n\n <\/tr>\n <\/tr>\n\n
Sequence:<\/td>\n200070871<\/td>\n<\/tr>\n
Name<\/td>\nUganda Heart Institute<\/td>\n<\/tr>\n
City<\/td>\nKampala<\/td>\n<\/tr>\n
Country<\/td>\nUganda<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Facility Contacts<\/h3>\n\n\n\n\n\n\n\n <\/tr>\n<\/table><\/div>\n
\n

Browse Interventions<\/h3>\n

Sequence:<\/td>\n28099187<\/td>\n<\/tr>\n
Facility Id<\/td>\n200070871<\/td>\n<\/tr>\n
Contact Type<\/td>\nprimary<\/td>\n<\/tr>\n
Name<\/td>\nEmmy H Okello<\/td>\n<\/tr>\n
Email<\/td>\nemmyoks@gmail.com<\/td>\n<\/tr>\n
Phone<\/td>\n+256775522284<\/td>\n<\/tr>\n
\n\n\n\n\n
Sequence:<\/td>\n96035961<\/td>\nSequence:<\/td>\n96035962<\/td>\nSequence:<\/td>\n96035963<\/td>\nSequence:<\/td>\n96035964<\/td>\nSequence:<\/td>\n96035965<\/td>\nSequence:<\/td>\n96035966<\/td>\nSequence:<\/td>\n96035967<\/td>\n<\/tr>\n
Mesh Term<\/td>\nPenicillins<\/td>\nMesh Term<\/td>\nPenicillin G<\/td>\nMesh Term<\/td>\nPenicillin G Benzathine<\/td>\nMesh Term<\/td>\nPenicillin G Procaine<\/td>\nMesh Term<\/td>\nPenicillin V<\/td>\nMesh Term<\/td>\nAnti-Bacterial Agents<\/td>\nMesh Term<\/td>\nAnti-Infective Agents<\/td>\n<\/tr>\n
Downcase Mesh Term<\/td>\npenicillins<\/td>\nDowncase Mesh Term<\/td>\npenicillin g<\/td>\nDowncase Mesh Term<\/td>\npenicillin g benzathine<\/td>\nDowncase Mesh Term<\/td>\npenicillin g procaine<\/td>\nDowncase Mesh Term<\/td>\npenicillin v<\/td>\nDowncase Mesh Term<\/td>\nanti-bacterial agents<\/td>\nDowncase Mesh Term<\/td>\nanti-infective agents<\/td>\n<\/tr>\n
Mesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Conditions<\/h3>\n\n\n\n\n
Sequence:<\/td>\n52161520<\/td>\n<\/tr>\n
Name<\/td>\nRheumatic Heart Disease<\/td>\n<\/tr>\n
Downcase Name<\/td>\nrheumatic heart disease<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Id Information<\/h3>\n\n\n\n\n <\/tr>\n <\/tr>\n <\/tr>\n<\/table><\/div>\n
\n

Countries<\/h3>\n

Sequence:<\/td>\n40151945<\/td>\n<\/tr>\n
Id Source<\/td>\norg_study_id<\/td>\n<\/tr>\n
Id Value<\/td>\n2022-0892<\/td>\n<\/tr>\n
\n\n\n\n
Sequence:<\/td>\n42561236<\/td>\n<\/tr>\n
Name<\/td>\nUganda<\/td>\n<\/tr>\n
Removed<\/td>\nFalse<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Groups<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n55583633<\/td>\nSequence:<\/td>\n55583634<\/td>\n<\/tr>\n
Group Type<\/td>\nExperimental<\/td>\nGroup Type<\/td>\nActive Comparator<\/td>\n<\/tr>\n
Title<\/td>\nOral Pencillin<\/td>\nTitle<\/td>\nIM Penicillin<\/td>\n<\/tr>\n
Description<\/td>\nOral phenoxymethyl penicillin (Pen V) prophylaxis 250mg twice daily.<\/td>\nDescription<\/td>\nIntramuscular benzathine benzylpenicillin G (BPG) prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children \u226530kg), every 28 days<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Interventions<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n52476897<\/td>\nSequence:<\/td>\n52476898<\/td>\n<\/tr>\n
Intervention Type<\/td>\nDrug<\/td>\nIntervention Type<\/td>\nDrug<\/td>\n<\/tr>\n
Name<\/td>\nphenoxymethyl penicillin<\/td>\nName<\/td>\nintramuscular benzathine penicillin G (BPG) prophylaxis<\/td>\n<\/tr>\n
Description<\/td>\nProphylaxis<\/td>\nDescription<\/td>\nProphylaxis<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Outcomes<\/h3>\n\n\n\n\n\n <\/tr>\n\n
Sequence:<\/td>\n177345379<\/td>\nSequence:<\/td>\n177345380<\/td>\nSequence:<\/td>\n177345381<\/td>\nSequence:<\/td>\n177345382<\/td>\nSequence:<\/td>\n177345383<\/td>\nSequence:<\/td>\n177345384<\/td>\nSequence:<\/td>\n177345385<\/td>\n<\/tr>\n
Outcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\n<\/tr>\n
Measure<\/td>\nProgression<\/td>\nMeasure<\/td>\nDemonstrate non-inferior costs and cost-effectiveness of oral penicillin compared to IM penicillin<\/td>\nMeasure<\/td>\nObtain cost data associated with the receipt of oral or IM penicillin in the community from a healthcare provider perspective.<\/td>\nMeasure<\/td>\nTreatment Acceptance<\/td>\nMeasure<\/td>\nTreatment Satisfaction<\/td>\nMeasure<\/td>\nHealth-Related Quality of Life<\/td>\nMeasure<\/td>\nPatient-reported outcomes<\/td>\n<\/tr>\n
Time Frame<\/td>\n2 year endpoint<\/td>\nTime Frame<\/td>\nbaseline, 6, 12, 18, 24 months post randomization<\/td>\nTime Frame<\/td>\n2 year endpoint<\/td>\nTime Frame<\/td>\nbaseline, 6, 12, 18, 24 months post randomization<\/td>\nTime Frame<\/td>\nbaseline, 6, 12, 18, 24 months post randomization<\/td>\nTime Frame<\/td>\nbaseline, 6, 12, 18, 24 months post randomization<\/td>\nTime Frame<\/td>\nbaseline, 6, 12, 18, 24 months post randomization<\/td>\n<\/tr>\n
Description<\/td>\nProgression of echocardiographic features of latent RHD to borderline to definite, or definite to mild or definite to moderate\/severe<\/td>\nDescription<\/td>\nThe aim is to understand the costs and effectiveness of the intervention. Costs will include intervention and disease specific costs, capturing both health system and family out of pocket costs. Participants will complete a questionnaire asking about out-of-pocket cost (medications, supplies, consultation fees) and lost productivity (including missed school and workdays) due to the intervention. Costs will be measured in the local currency (Uganda Shillings) and presented in United States dollars (USD)<\/td>\nDescription<\/td>\nIn order to understand health center and community costs, 10 randomly selected health care facilities (including level II, III, and IV facilities) will be surveyed to obtain direct costs of medications, supplies as well as any administration and professional fees associated with outpatient and inpatient visits.<\/td>\nDescription<\/td>\nTreatment acceptance will be assessed with the widely-used Chronic Treatment Acceptance (ACCEPT) questionnaire, a generic medication acceptance instrument validated for chronic conditions. This 25-item survey consists of six areas of focus: medication convenience (3 items), length of treatment (2 items), medication constraints (9 items), medication side effects (5 items), medication effectiveness (3 items), medication advantages (3 items). Responses are rated on a 5-point Likert scale and scores of 1 through 4 indicating increasing levels of acceptance.<\/td>\nDescription<\/td>\nTreatment Satisfaction will be assessed with the 14-item Abbreviated Treatment Satisfaction Questionnaire (v 1.4). This widely used survey contains 4 areas of focus including satisfaction of treatment effectiveness (3 items), satisfaction with treatment side effects (5 items), satisfaction with treatment convenience (3 items), and a global treatment satisfaction (3 items). Scores are then transformed to a score of 0-100 to create the overall scale score and the subcategory scores, with higher scores representing higher treatment satisfaction on that domain.<\/td>\nDescription<\/td>\nHealth Related Quality of Life will be measured using the Pediatric Quality of Life Inventory Version 4.0 Generic Core (PedsQL 4.0) questionnaire. The PedsQLTM4.0 is a 23-item survey for children aged 5-18 which assesses HRQOL. It has four areas of focus: Physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), school functioning (5 items). Each item has five possible responses measuring the extent to which the item was a problem during the past month. The possible responses are measured using a 5-point Likert scale from 0=never a problem to 4 = almost always a problem. These reverse scaled scores are then transformed to a score of 0-100 to create the overall scaled score and the subcategory scores, with higher scores representing better quality of life.<\/td>\nDescription<\/td>\nInterviews will be used to collect qualitative data around participants perceptions of the impact of RHD and its treatment on their activities of daily living and quality of life including experiences with IM or oral penicillin prophylaxis.<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Browse Conditions<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n193451646<\/td>\nSequence:<\/td>\n193451647<\/td>\nSequence:<\/td>\n193451648<\/td>\nSequence:<\/td>\n193451649<\/td>\nSequence:<\/td>\n193451650<\/td>\nSequence:<\/td>\n193451651<\/td>\nSequence:<\/td>\n193451652<\/td>\nSequence:<\/td>\n193451653<\/td>\nSequence:<\/td>\n193451654<\/td>\nSequence:<\/td>\n193451655<\/td>\nSequence:<\/td>\n193451656<\/td>\nSequence:<\/td>\n193451657<\/td>\n<\/tr>\n
Mesh Term<\/td>\nRheumatic Heart Disease<\/td>\nMesh Term<\/td>\nRheumatic Diseases<\/td>\nMesh Term<\/td>\nHeart Diseases<\/td>\nMesh Term<\/td>\nCardiovascular Diseases<\/td>\nMesh Term<\/td>\nMusculoskeletal Diseases<\/td>\nMesh Term<\/td>\nConnective Tissue Diseases<\/td>\nMesh Term<\/td>\nRheumatic Fever<\/td>\nMesh Term<\/td>\nStreptococcal Infections<\/td>\nMesh Term<\/td>\nGram-Positive Bacterial Infections<\/td>\nMesh Term<\/td>\nBacterial Infections<\/td>\nMesh Term<\/td>\nBacterial Infections and Mycoses<\/td>\nMesh Term<\/td>\nInfections<\/td>\n<\/tr>\n
Downcase Mesh Term<\/td>\nrheumatic heart disease<\/td>\nDowncase Mesh Term<\/td>\nrheumatic diseases<\/td>\nDowncase Mesh Term<\/td>\nheart diseases<\/td>\nDowncase Mesh Term<\/td>\ncardiovascular diseases<\/td>\nDowncase Mesh Term<\/td>\nmusculoskeletal diseases<\/td>\nDowncase Mesh Term<\/td>\nconnective tissue diseases<\/td>\nDowncase Mesh Term<\/td>\nrheumatic fever<\/td>\nDowncase Mesh Term<\/td>\nstreptococcal infections<\/td>\nDowncase Mesh Term<\/td>\ngram-positive bacterial infections<\/td>\nDowncase Mesh Term<\/td>\nbacterial infections<\/td>\nDowncase Mesh Term<\/td>\nbacterial infections and mycoses<\/td>\nDowncase Mesh Term<\/td>\ninfections<\/td>\n<\/tr>\n
Mesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Sponsors<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n48310897<\/td>\nSequence:<\/td>\n48310898<\/td>\n<\/tr>\n
Agency Class<\/td>\nOTHER<\/td>\nAgency Class<\/td>\nOTHER<\/td>\n<\/tr>\n
Lead Or Collaborator<\/td>\nlead<\/td>\nLead Or Collaborator<\/td>\ncollaborator<\/td>\n<\/tr>\n
Name<\/td>\nChildren's Hospital Medical Center, Cincinnati<\/td>\nName<\/td>\nUganda Heart Institute<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Overall Officials<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n29280699<\/td>\n<\/tr>\n
Role<\/td>\nPrincipal Investigator<\/td>\n<\/tr>\n
Name<\/td>\nAndrea Z Beaton<\/td>\n<\/tr>\n
Affiliation<\/td>\nCincinnati Chidren's hospital<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Central Contacts<\/h3>\n\n\n\n\n\n\n <\/tr>\n\n
Sequence:<\/td>\n12006034<\/td>\nSequence:<\/td>\n12006035<\/td>\n<\/tr>\n
Contact Type<\/td>\nprimary<\/td>\nContact Type<\/td>\nbackup<\/td>\n<\/tr>\n
Name<\/td>\nNdate Fall, MS RN<\/td>\nName<\/td>\nMary Banks<\/td>\n<\/tr>\n
Phone<\/td>\n15135171327<\/td>\n<\/tr>\n
Email<\/td>\nndate.fall@cchmc.org<\/td>\nEmail<\/td>\nmary.Banks@cchmc.org<\/td>\n<\/tr>\n
Role<\/td>\nContact<\/td>\nRole<\/td>\nContact<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Group Interventions<\/h3>\n\n\n\n\n
Sequence:<\/td>\n68137455<\/td>\nSequence:<\/td>\n68137456<\/td>\n<\/tr>\n
Design Group Id<\/td>\n55583633<\/td>\nDesign Group Id<\/td>\n55583634<\/td>\n<\/tr>\n
Intervention Id<\/td>\n52476897<\/td>\nIntervention Id<\/td>\n52476898<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Eligibilities<\/h3>\n\n\n <\/tr>\n\n\n\n\n <\/tr>\n\n <\/tr>\n <\/tr>\n\n\n\n
Sequence:<\/td>\n30760339<\/td>\n<\/tr>\n
Gender<\/td>\nAll<\/td>\n<\/tr>\n
Minimum Age<\/td>\n5 Years<\/td>\n<\/tr>\n
Maximum Age<\/td>\n17 Years<\/td>\n<\/tr>\n
Healthy Volunteers<\/td>\nNo<\/td>\n<\/tr>\n
Criteria<\/td>\nInclusion Criteria: Has a new diagnosis of latent RHD detected through primary or secondary school echocardiographic screening. Has agreed to participate in the study via the study's informed consent\/assent process. Operational Definition of Latent RHD Borderline RHD or Mild Definite RHD (to include no more than mild regurgitation at the mitral or aortic valve, normal mean mitral and aortic valve gradients, normal bi-ventricular function) according to the 2012 WHF consensus criteria. Exclusion Criteria: Known history of ARF or RHD Newly diagnosed RHD by echo screening considered to be "missed clinical RHD" as compared to true latent RHD including: > mild pathological valvular regurgitation at the mitral valve or aortic valve, mitral stenosis (mean MV gradient \u2265 4mmHg) (definite B61), aortic stenosis (mean AV gradient \u2265 20mmHg) Structural or functional cardiac defects, other than those consistent with RHD, that were known prior to or detected through echo screening (except patent foramen ovale, small atrial septal defect, small ventricular septal defect, small patent ductus arteriosus) Self-report of prior allergic reaction to penicillin Any known conditions predisposing to thrombocytopenia or hypercoagulability, or other contraindications to intramuscular injection Any known co-morbid conditions (ex. HIV, renal deficiencies, severe malnutrition) that have resulted in prescription of regular antibiotic prophylaxis)<\/td>\n<\/tr>\n
Adult<\/td>\nFalse<\/td>\n<\/tr>\n
Child<\/td>\nTrue<\/td>\n<\/tr>\n
Older Adult<\/td>\nFalse<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Calculated Values<\/h3>\n\n\n\n <\/tr>\n <\/tr>\n\n <\/tr>\n <\/tr>\n\n <\/tr>\n\n\n\n\n\n\n\n\n <\/tr>\n<\/table><\/div>\n
\n

Designs<\/h3>\n

Sequence:<\/td>\n254261870<\/td>\n<\/tr>\n
Number Of Facilities<\/td>\n1<\/td>\n<\/tr>\n
Registered In Calendar Year<\/td>\n2023<\/td>\n<\/tr>\n
Were Results Reported<\/td>\nFalse<\/td>\n<\/tr>\n
Has Us Facility<\/td>\nFalse<\/td>\n<\/tr>\n
Has Single Facility<\/td>\nTrue<\/td>\n<\/tr>\n
Minimum Age Num<\/td>\n5<\/td>\n<\/tr>\n
Maximum Age Num<\/td>\n17<\/td>\n<\/tr>\n
Minimum Age Unit<\/td>\nYears<\/td>\n<\/tr>\n
Maximum Age Unit<\/td>\nYears<\/td>\n<\/tr>\n
Number Of Primary Outcomes To Measure<\/td>\n1<\/td>\n<\/tr>\n
Number Of Secondary Outcomes To Measure<\/td>\n6<\/td>\n<\/tr>\n
\n\n\n\n\n\n\n\n <\/tr>\n <\/tr>\n <\/tr>\n <\/tr>\n <\/tr>\n\n
Sequence:<\/td>\n30506543<\/td>\n<\/tr>\n
Allocation<\/td>\nRandomized<\/td>\n<\/tr>\n
Intervention Model<\/td>\nParallel Assignment<\/td>\n<\/tr>\n
Observational Model<\/td>\n<\/td>\n<\/tr>\n
Primary Purpose<\/td>\nTreatment<\/td>\n<\/tr>\n
Time Perspective<\/td>\n<\/td>\n<\/tr>\n
Masking<\/td>\nSingle<\/td>\n<\/tr>\n
Outcomes Assessor Masked<\/td>\nTrue<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Intervention Other Names<\/h3>\n\n\n\n\n
Sequence:<\/td>\n26668216<\/td>\nSequence:<\/td>\n26668217<\/td>\n<\/tr>\n
Intervention Id<\/td>\n52476897<\/td>\nIntervention Id<\/td>\n52476898<\/td>\n<\/tr>\n
Name<\/td>\nPen V<\/td>\nName<\/td>\nbenzathine penicillin G, BPG, penicillin prophylaxis<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Responsible Parties<\/h3>\n\n\n\n <\/tr>\n <\/tr>\n <\/tr>\n <\/tr>\n <\/tr>\n<\/table><\/div>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"

Studies Study First Submitted Date 2023-01-04 Study First Posted Date 2023-01-23 Last Update Posted Date 2023-05-08 Start Month Year April 1, 2024 Primary Completion Month Year March 31, 2027 Verification Month Year May 2023 Verification Date 2023-05-31 Last Update Posted Date 2023-05-08 Detailed Descriptions Sequence: 20718240 Description GOALIS is a randomized controlled trial developed to […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":154761,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/154760"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=154760"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/154760\/revisions"}],"predecessor-version":[{"id":566715,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/154760\/revisions\/566715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/154761"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=154760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=154760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=154760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Sequence:<\/td>\n28872819<\/td>\n<\/tr>\n
Responsible Party Type<\/td>\nSponsor<\/td>\n<\/tr>\n